Thiotepa, Etoposide, Cyclophosphamide, ARA-C and Melphalan (TECAM) conditioning regimen for autologous stem cell transplantation in lymphoma

High dose chemotherapy and autologous stem cell transplantation (ASCT) is the current standard of care for relapsed non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). Conditioning regimens with high dose BCNU are associated with Idiopathic Pneumonitis Syndrome (IPS). We therefore created a modified alternative TECAM conditioning regimen, consisting of etoposide, thiotepa, cytarabine, cyclophosphamide and melphalan. We retrospectively analyzed our cohort of NHL and HL patients, who underwent ASCT with the TECAM conditioning between 2000 and 2013.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research